Casdin Capital’s Intellia Therapeutics NTLA Stock Holding History

Casdin Capital’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.01M	Hold	355,000	–	–	0.3%	31
2026 Q1	$4.55M	Buy	+355,000	New	+$4.52M	0.34%	28
2025 Q2	–	Sell	-2,000,000	Closed	-$14.2M	–	39
2025 Q1	$14.2M	Hold	2,000,000	–	–	1.16%	16
2024 Q4	$23.3M	Hold	2,000,000	–	–	1.55%	15
2024 Q3	$41.1M	Hold	2,000,000	–	–	2.74%	11
2024 Q2	$44.8M	Buy	2,000,000 +125,000	+7%	+$2.98M	3.42%	9
2024 Q1	$51.6M	Buy	1,875,000 +425,000	+29%	+$11.8M	3.83%	8
2023 Q4	$44.2M	Buy	1,450,000 +271,925	+23%	+$7.82M	4.34%	6
2023 Q3	$37.3M	Sell	1,178,075 -96,925	-8%	-$3.76M	4.12%	8
2023 Q2	$52M	Hold	1,275,000	–	–	4.54%	6
2023 Q1	$47.5M	Buy	1,275,000 +980,000	+332%	+$38.4M	3.91%	7
2022 Q4	$10.3M	Hold	295,000	–	–	0.8%	30
2022 Q3	$16.5M	Buy	+295,000	New	+$18.3M	1.08%	19

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Casdin Capital's NTLA Position: Q2 2026 in Review

Casdin Capital held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 355,000 shares worth $6.01M. The position accounts for 0.3% of the portfolio, ranked #31.

Casdin Capital first reported a position in NTLA in Q3 2022 and has held it in 13 quarters since. The position peaked at $52M in Q2 2023. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Casdin Capital held 355,000 shares of Intellia Therapeutics worth $6.01M as of Q2 2026.
Casdin Capital left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up 0.3% of Casdin Capital's portfolio in Q2 2026, its #31 holding.
Casdin Capital first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 13 quarters since.
Casdin Capital's Intellia Therapeutics position peaked at $52M in Q2 2023.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.